SWP
ACAD icon

Stratos Wealth Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Stratos Wealth Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-220
Closed -$7K – 3102
2017
Q4 		$7K Buy
+220
New +$7.04K ﹤0.01% 2260

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Stratos Wealth Partners's ACAD Position: Q1 2018 in Review

Stratos Wealth Partners sold out of Acadia Pharmaceuticals (ACAD) in Q1 2018, closing a stake of 220 shares — an estimated $7K sold.

Stratos Wealth Partners first reported a position in ACAD in Q4 2017 and held it in 1 quarter. The position peaked at $7K in Q4 2017. 196 funds tracked by Wall St. Rank hold ACAD as of Q1 2018.

  • Stratos Wealth Partners reported no remaining Acadia Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Stratos Wealth Partners sold 220 Acadia Pharmaceuticals shares in Q1 2018, an estimated $7K.
  • Stratos Wealth Partners first reported a position in Acadia Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Stratos Wealth Partners's Acadia Pharmaceuticals position peaked at $7K in Q4 2017.
  • 196 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2018.

Based on Stratos Wealth Partners's 13F filing for Q1 2018, filed 10 May 2018.